Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 6/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11201231 | 0.83 | MMP12 (0.38) | MMP12CYP1A2CYP2A6METAP1ALDH1A1 | |
| SCHEMBL14319844 | 0.80 | METAP1 (0.36) | MMP12METAP1ALDH1A1GAAMAPT | |
| SCHEMBL8577915 | 0.79 | ALDH1A1 (0.34) | CYP1A2CYP2A6METAP1ACHEALDH1A1 | |
| SCHEMBL8533498 | 0.77 | — | — | |
| Chloromethane SCHEMBL6475054 | 0.75 | AHR (0.40) | MAPT | |
| SCHEMBL90933 | 0.75 | MMP12 (0.36) | MMP12CYP1A2CYP2A6ALDH1A1GAA | |
| SCHEMBL15128666 | 0.75 | METAP1 (0.39) | MMP12CYP1A2CYP2A6METAP1ACHE | |
| SCHEMBL6737529 | 0.74 | — | — | |
| SCHEMBL2098339 | 0.74 | CA9 (0.40) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL11816254 | 0.74 | AHR (0.43) | CYP1A2METAP1MAPTPARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MMP12 1703/4885CYP1A2 2958/4885CYP2A6 2582/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | MMP12 351/4885CYP1A2 1349/4885CYP2A6 1014/4885 |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MMP12 3133/4885CYP1A2 2253/4885CYP2A6 2408/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MMP12 3133/4885CYP1A2 2253/4885CYP2A6 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.